EPWORTH – For years, the rhythm of HIV prevention for Melody Dengu was measured in 24-hour increments. One pill, every day, without fail. But in the shadows of her career as a sex worker in one of Zimbabwe’s busiest hubs, that daily ritual was more than a medical necessity—it was a liability.
Melody was speaking at the twice-yearly HIV prevention injectable launch of Lenacapavir in Epworth on 19 February, 2026.
”Carrying tablets has exposed some of us to gender-based violence,” Melody said, her voice steady but firm.
“When clients see the pills, they assume we are taking ARVs for treatment. They don’t understand it’s prevention.”
Today, Melody is the face of a new era. She is one of the first Zimbabweans to receive Lenacapavir, a breakthrough long-acting injectable that requires only two doses a year. No pills to hide, no daily reminders of risk—just a twice-yearly shield that is reshaping the landscape of public health in Southern Africa, the region burdened by HIV.
The prevention choice is now a ‘Toolbox Reimagined’. It has brought power across the gender diversity.
The national rollout, launched this week by the Ministry of Health and Child Care, (MoHCC) marks a decisive escalation in Zimbabwe’s strategy to curb stubborn infection rates. While the country has made massive strides in HIV management, global prevention efforts have plateaued, with 1.3 million new infections recorded worldwide in 2024.
Health Minister Dr. Douglas Mombeshora is positioning Lenacapavir not as a replacement preventative tool for old methods, but as a high-tech “power tool” in an expanding arsenal.
”This rollout has not happened by chance,” Dr Mombeshora told crowds in Epworth.
“It is deliberate and backed by strong policy foundations. Every innovation must strengthen our health systems and serve the people who need it most. It is complementing what is already in use.”
DISCREET
As stated by Melody, Lenacapavir is the ‘Science of Discretion’.
Biologically, Lenacapavir is a capsid inhibitor.
Unlike older drugs, it disrupts the HIV virus at multiple stages of its life cycle. Because it is released slowly into the bloodstream from the injection site, it maintains protective levels for a full six months.
For high-risk populations, the benefits are as much social as they are medical, it strengthens adherence as it eliminates “pill fatigue.”
The risk of missed daily doses becomes history, it values privacy as there are no medication bottles to hide.
In the African context, talking of sex is taboo.It is one act widely practised without discussing. In such cases, carrying oral prevention pills risked one to be questioned. There, too was confusion for those not in the know, it was not clear if one was taking treatment or prevention.
Lenacapavir is
deal for highly mobile populations who may not have regular access to refills.
INFODEMIC
Fighting the “Infodemic”
The greatest hurdle to the rollout isn’t the science—it’s the rumours. As the programme expands, officials are battling a wave of misinformation regarding side effects and “body deformities.”
Melody Dengu has taken it upon herself to be a “community champion,” debunking myths with her own experience. “Apart from pain in the first few hours after the injection, nothing has changed,” she said.
Her advocacy has already brought 12 of her colleagues to the clinic to seek the injection.
ROAD AHEAD
The Epworth launch is the first domino in a wider national strategy. While condoms, voluntary medical male circumcision (VMMC), and daily oral PrEP remain central to the response, the introduction of a twice-yearly injectable offers a level of “protection, dignity, and peace of mind” that was previously unthinkable.
As Dr Benard Madzima, CEO of the National AIDS Council, emphasized: “We are adding another powerful tool to the toolbox. We aren’t abandoning what works; we are making it better.”
Zimbabwe marks a milestone as 24 sites will be rolling out Lenacapavir shortly.
The launch targeted high-risk individuals, including sex workers, adolescent girls, and mobile workers.
Health Minister Dr Douglas Mombeshora emphasized the importance of trusting healthcare professionals, saying: “This is a matter of life and health, so let us be very clear. Do not place your trust in rumours. Do not risk your wellbeing on misinformation.” he added.
“Today marks an important day in Zimbabwe’s national response to HIV. We gather here to launch lenacapavir – a long-acting injectable option for HIV prevention – and to show our commitment to protecting life and ending AIDS as a public health issue,” said Dr Mombeshora.
The twice-yearly injection is expected to improve adherence and expand choice in HIV prevention services, addressing concerns around daily oral PrEP pills.
With 1.3 million new deaths recorded globally in 2024, Zimbabwe’s rollout signals a strategic escalation in the fight against HIV. The initiative targets key populations first, with wider expansion planned as capacity grows, aiming to reshape the country’s HIV prevention response.
In 2024, Zimbabwe recorded around 13 500 new deaths with 17 thousand infections related to AIDS. (NAC)
One death is one too much.
It is high time we closed the deaths tap.
Feedback: [email protected]


